Abstract
Heparan sulfate proteoglycans interact with many extracellular matrix constituents, growth factors and enzymes. Degradation of heparan sulfate by endoglycosidic heparanase cleavage affects a variety of biological processes. We have purified a 50-kDa heparanase from human hepatoma and placenta, and now report cloning of the cDNA and gene encoding this enzyme. Expression of the cloned cDNA in insect and mammalian cells yielded 65-kDa and 50-kDa recombinant heparanase proteins. The 50-kDa enzyme represents an N-terminally processed enzyme, at least 100-fold more active than the 65-kDa form. The heparanase mRNA and protein are preferentially expressed in metastatic cell lines and specimens of human breast, colon and liver carcinomas. Low metastatic murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquired a highly metastatic phenotype in vivo, reflected by a massive liver and lung colonization. This represents the first cloned mammalian heparanase, to our knowledge, and provides direct evidence for its role in tumor metastasis. Cloning of the heparanase gene enables the development of specific molecular probes for early detection and treatment of cancer metastasis and autoimmune disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kjellen, L. & Lindahl, U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443– 475 (1991).
David, G. Integral membrane heparan sulfate proteoglycan. FASEB J. 7, 1023–1030 (1993).
Jackson, R.L., Busch, S.J. & Cardin, A.L. Glycosaminoglycans: Molecular properties, protein interactions and role in physiological processes. Physiol. Rev. 71, 481–539 (1991).
Wight, T.N., Kinsella, M.G. & Qwarnstromn, E.E. The role of proteoglycans in cell adhesion, migration and proliferation. Curr. Opin. Cell Biol. 4, 793–801 (1992).
Rapraeger, A.C. The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr. Opin. Cell Biol. 5, 844– 853 (1993).
Wight, T.N. Cell biology of arterial proteoglycans. Arteriosclerosis 9, 1–20 (1989).
Vlodavsky, I., Fuks, Z., Bar-Ner, M., Ariav, Y. & Schirrmacher, V. Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res. 43, 2704–2711 (1983).
Nakajima, M., Irimura, T., DiFerrante, D., DiFerrante, N. & Nicholson, G.L. Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B16 melanoma sublines. Science 220, 611– 613 (1983).
Nakajima, M., Irimura, T. & Nicolson, G.L. Heparanase and tumor metastasis. J. Cell. Biochem. 36, 157–167 (1988).
Vlodavsky, I. et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14, 290– 302 (1995).
Parish, C.R., Coombe, D.R., Jakobsen, K.B. & Underwood, P.A. Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor cell-derived heparanase. Int. J. Cancer 40, 511–517 (1987).
Lider, O. et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with heparinoid inhibitors of T lymphocyte heparanase. J. Clin. Invest. 83, 752–756 (1989).
Willenborg, D. O. & Parish, C. R. Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. J. Immunol. 140, 3401– 3405 (1988).
Vlodavsky, I. et al. Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112– 127 (1992).
Graham, L.D. & Underwood, P.A. Comparison of the heparanase enzymes from mouse melanoma cells, mouse macrophages and human platelets. Biochem. Mol. Biol. 39, 563– 571 (1996).
Ishai-Michaeli, R., Eldor, A. & Vlodavsky, I. Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Reg. 1, 833– 842 (1990).
Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P. & Fuks, Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem. Sci. 16, 268–271 (1991).
Eisenberg, S., Sehayek, E., Olivecrona, T. & Vlodavsky, I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J. Clin. Invest. 90, 2013–2021 (1992).
Oosta, G.M., Favreau, L.V., Beeler, D.L. & Rosenberg, R.D. Purification and properties of human platelet heparitinase. J. Biol. Chem. 257, 11249–11255 (1982).
Freeman, C. & Parish, C.R. Human platelet heparanase: Purification, characterization and catalytic activity. Biochem. J. 330, 1341–1350 (1998).
Hoogewerf, A.J. et al. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J. Biol. Chem. 270, 3268– 3277 (1995).
Gonzalo, V. et al. Partial sequence of human platelet heparitinase and evidence of its ability to polymerize. Biochim. Biophys. Acta 1429, 431–438 (1999).
Jin, L., Nakajima, M. & Nicolson, G.L. Immunochemical localization of heparanase in mouse and human melanoma. Int. J. Cancer 45, 1088–1095 (1990).
De Vouge, M.W. et al. Immunoselection of GRP94/Endoplasmin from a KNRK cell specific g gt11 library using antibodies directed against a putative heparanase amino-terminal peptide. Int. J. Cancer 56, 286– 294 (1994).
Goshen, R. et al. Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. Mol. Hum. Reprod. 2, 679–684 (1996).
Bar-Ner, M., Eldor, A., Wasserman, L., Matzner, Y. & Vlodavsky, I. Inhibition of heparanase mediated degradation of extracellular matrix heparan sulfate by modified and non-anticoagulant heparin species. Blood 70, 551–557 (1987).
Even-Ram, S. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med. 8, 909– 914 (1998).
Larizza, L., Schirrmacher, V. & Pfluger, E. Acquisition of high metastatic capacity after in vitro fusion of a non-metastatic tumor line with a bone marrow derived macrophage. J. Exp. Med. 160, 1579– 1584 (1984).
Klein, U. & Figura, K.V. Substrate specificity of a heparan-sulfate degrading endoglucuronidase from human placenta. Hoppe-Seyler's Z Physiol. Chem. 360, 1465–1471 (1979).
Bame, K. J., & Robson K. Heparanases produce distinct populations of heparan sulfate glycosaminoglycans in Chinese hamster ovary cells. J. Biol. Chem. 272, 2245–2251 (1997).
Sandback-Pikas, D., Li, J-P., Vlodavsky, I. & Lindahl, U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273, 18770–18777 (1998).
Pillarisetti, S. et al. Endothelial cell heparanase modulation of lipoprotein lipase activity. J. Biol. Chem. 272, 15753– 15759 (1997).
Yahalom, J., Eldor, A., Fuks, Z. & Vlodavsky, I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J. Clin. Invest. 74, 1842–1849 (1984).
Bashkin, P., Razin, E., Eldor, A. & Vlodavsky, I. Degranulating mast cells secrete an endoglycosidase which degrades heparan sulfate in subendothelial extracellular matrix. Blood 75, 2204– 2212 (1990).
Matzner, Y. et al. Degradation of heparan sulfate in the subendothelial basement membrane by a readily released heparanase from human neutrophils. J. Clin. Invest. 76, 1306–1313 (1985).
Naparstek, Y., Cohen, I.R., Fuks, Z. & Vlodavsky, I. Activated T lymphocytes produce a matrix-degrading heparan sulfate endoglycosidase. Nature 310, 241–243 (1984).
Peretz, T. et al. Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimens. Int. J. Cancer 45, 1054–1060 (1990).
Kleiner, D. E. & Stetler-Stevenson, W. G. Structural biochemstry and activation of matrix metalloproteases. Curr. Opin. Cell Biol. 5, 891–897 (1993).
Stetler-Stevenson, W. G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9, 289–303 (1990).
Mignatti, P. & Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161–195 (1993).
Bar-Ner, M. et al. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int. J. Cancer 35, 483–491 (1985).
Vlodavsky, I. et al. in Tumor Angiogenesis (eds. Lewis, C.E., Bicknell, R &Ferrara, N.) 125–140 (Oxford University Press, Oxford, UK, 1997).
Vlodavsky, I., Bar-Shavit, R., Korner, G. & Fuks, Z. in Basement Membranes: Cellular and Molecular Aspects (eds. Rohrbach, D.H. & Timpl, R.) 327–343 (Academic, Orlando, Florida, 1993).
Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P. & Ornitz, D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841– 848 (1991).
Miao, H-Q., Ornitz, D. M., Eingorn, E., Ben-Sasson, S. A. & Vlodavsky I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J. Clin. Invest. 99, 1565–1575 (1997).
Vlodavsky, I. et al. Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA 84, 2292–2296 (1987).
Vlodavsky, I. & Christofori, G. in Antiangiogenic Agents in Cancer Therapy (ed. Teicher, B.A.) 93–118 (Humana, Totowa, New Jersey, 1998).
Soule, H.D. et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50, 6075–6086 (1990).
Vlodavsky, I. in Current protocols in Cell Biology, Vol. I, Suppl. I (eds. Bonifacino, J.S., Dasso, M, Harford, J.B, Lippincott-Schwartz, J & Yamada, K.M.) 10.4.1–10.4.14 (John Wiley & Sons, New York, New York, 1999).
Savitsky, K. et al. Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-translational regulation of ATM gene expression. Nucleic Acids Res. 25, 1678– 1684 (1997).
Acknowledgements
We thank D. Melamed, E. Feinstein, O. Yacoby-Zeevi, M. Ayal-Hershkovitz, E. Levi and Z. Rangini-Gueta for encouragement, discussions and assistance. This work was supported by grants from the Israel Science Foundation administered by the Israel Academy of Sciences and Humanities; The Israel Cancer Research Fund (ICRF), the GSF (German Forschungszentrum fur umwelt und gesundheit) (BMBF-MOS); and InSight.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vlodavsky, I., Friedmann, Y., Elkin, M. et al. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5, 793–802 (1999). https://doi.org/10.1038/10518
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/10518
This article is cited by
-
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
npj Breast Cancer (2021)
-
Heparanase modulation by Wingless/INT (Wnt)
Molecular Biology Reports (2021)